Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
Retrieved on:
Tuesday, October 20, 2020
General Health, Infectious diseases, Health, Pharmaceutical, Clinical trials, Vaccines, Medical specialties, Pneumonia, Microbiology, Clinical medicine, Pneumococcal conjugate vaccine, Vaccination, Conjugate vaccine, Vaccine, Streptococcus pneumoniae, PNEU-PATH, PNEU-DAY, V114, Pneumococcal Disease, Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the companys investigational 15-valent pneumococcal conjugate vaccine.
Key Points:
- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the companys investigational 15-valent pneumococcal conjugate vaccine.
- V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies.
- Findings from the V114 Phase 3 clinical program in adults, including PNEU-PATH and PNEU-DAY, will be presented at a future scientific congress.
- V114 is Mercks investigational 15-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of pneumococcal disease in adults and children.